Mode
Text Size
Log in / Sign up
Phase 3 Completed N=92 Other

Liver and Fat Regulation in Overweight Adolescent Girls

Source: ClinicalTrials.gov NCT02157974 ↗
Enrolled (actual)
92
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcomePrimary: Hepatic Glucose Release — 1.85; 1.46; 1.54; 1.88 mg/kg/min
◆ Published Evidence
Established
85citations · ~12 / year
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
The Journal of clinical endocrinology and metabolism · 2019 · Open access · Likely link

Summary

Women with polycystic ovarian syndrome (PCOS) have increased rates of hepatic steatosis compared to weight similar women with regular menses. It is unclear if this is related to high testosterone or insulin resistance. The investigators will assess hepatic glucose release, rates of lipolysis and hepatic de novo lipogenesis in the fasted and postprandial state to determine if alterations in the processes contribute to hepatic steatosis. Participants will be overweight, sedentary girls with or without PCOS. Those with PCOS will either be medication naive, or must be taking metformin or combined oral contraceptives (COCPs) for a period of at least 6 months prior to study procedures.

Linked Publications (3)

  • Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
    The Journal of clinical endocrinology and metabolism · 2019 · 85 citations · Open access · Likely link
  • Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index).
    Clinical endocrinology · 2019 · 32 citations · Open access · Likely link
  • Relative Skeletal Muscle Mass Is Associated With Hepatic Steatosis in Adolescents With Overweight and Obesity.
    Pediatric obesity · 2026 · 0 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Hepatic Glucose Release
1.85; 1.46; 1.54; 1.88; 1.57
SECONDARY
Hepatic Phosphate Concentrations
0.167684728; 0.198640255; 0.198787476; 0.186923469; 0.067905319; 0.077949656
SECONDARY
Rates of Lipolysis
0.54; 0.49; 0.49; 0.78; 0.65
SECONDARY
Hepatic Fat Fraction
4.1; 7.6; 6.9; 6.8; 13.3
SECONDARY
Hepatic de Novo Lipogenesis
9.3; 6.6; 7.9; 18.2; 19.4

Eligibility Criteria

Inclusion Criteria

  • Females
  • 2 years post-menarche
  • BMI percentile >90%

Exclusion Criteria

  • Type 2 diabetes
  • Anemia
  • Liver disease
  • Medications known to effect insulin sensitivity
  • Cause of oligomenorrhea or hirsutism other than PCOS,
  • >3 hours a week of moderate exercise.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02157974) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search